Sofinnova closes its second crossover fund at €725M, topping its €650M target, to back about 15 late-stage European biotechs ...
The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ...
For the third time in about two years, the FDA has cited manufacturing deficiencies in rejecting a drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics ...
Welcome back to another edition of Endpoints Weekly! The unseasonably warm autumn we’ve had in New York finally seems to be ...
Neurosterix raises $105M Series B for M4 PAM schizophrenia drug NTX-253, adding Karuna’s Andrew Miller as executive chair.
Rezera, a biotech developing drugs for cardio and inflammatory diseases, has delayed its IPO scheduled for Friday, a company ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
J&J’s trispecific ramantamig shows 100% ORR in newly diagnosed myeloma, Tibsovo hits EFS in frontline AML, Calquence combo ...
HHS announced ~$25M for psychedelics research, focusing on ibogaine via ARPA-H. Mark Cuban's Cost Plus Drugs and Beond will ...
Companies that committed to President Donald Trump’s drug pricing policy now face difficult decisions when launching new ...
Mirum’s hepatitis D drug brelovitug hits its Phase 3 goal in AZURE-4, setting up a 2027 filing against Gilead’s Hepcludex and ...
Oyster Therapeutics raises $60M Series A-2, with Lilly joining, for self-assembling oral degraders that target toxic tau in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results